- Home
- CFBK vs MCRB Comparison
CFBK vs MCRB Comparison
Compare CFBK & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- MCRB
- Stock Information
- Founded
- CFBK 1892
- MCRB 2010
- Country
- CFBK United States
- MCRB United States
- Employees
- CFBK N/A
- MCRB N/A
- Industry
- CFBK Major Banks
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- CFBK Finance
- MCRB Health Care
- Exchange
- CFBK Nasdaq
- MCRB Nasdaq
- Market Cap
- CFBK 159.5M
- MCRB 144.6M
- IPO Year
- CFBK 1998
- MCRB 2015
- Fundamental
- Price
- CFBK $24.12
- MCRB $19.97
- Analyst Decision
- CFBK Buy
- MCRB Hold
- Analyst Count
- CFBK 1
- MCRB 4
- Target Price
- CFBK $29.00
- MCRB $14.33
- AVG Volume (30 Days)
- CFBK 32.8K
- MCRB 196.3K
- Earning Date
- CFBK 10-29-2025
- MCRB 11-12-2025
- Dividend Yield
- CFBK 1.32%
- MCRB N/A
- EPS Growth
- CFBK 36.66
- MCRB N/A
- EPS
- CFBK 2.77
- MCRB 10.22
- Revenue
- CFBK $52,793,000.00
- MCRB N/A
- Revenue This Year
- CFBK $39.98
- MCRB N/A
- Revenue Next Year
- CFBK $10.47
- MCRB N/A
- P/E Ratio
- CFBK $8.73
- MCRB $2.00
- Revenue Growth
- CFBK 20.91
- MCRB N/A
- 52 Week Low
- CFBK $19.23
- MCRB $6.53
- 52 Week High
- CFBK $31.17
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- CFBK 47.27
- MCRB 56.40
- Support Level
- CFBK $23.65
- MCRB $19.14
- Resistance Level
- CFBK $24.44
- MCRB $21.50
- Average True Range (ATR)
- CFBK 0.37
- MCRB 1.46
- MACD
- CFBK -0.05
- MCRB 0.13
- Stochastic Oscillator
- CFBK 38.16
- MCRB 69.59
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.